Thoms, Kai-Martin

[["dc.bibliographiccitation.firstpage","582"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","609"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Kähler, Katharina C."],["dc.contributor.author","Hassel, Jessica C."],["dc.contributor.author","Heinzerling, Lucie"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Thoms, Kai‐Martin"],["dc.contributor.author","Ugurel, Selma"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Gutzmer, Ralf"],["dc.date.accessioned","2021-04-14T08:25:27Z"],["dc.date.available","2021-04-14T08:25:27Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1111/ddg.14128"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81631"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.title","Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","12"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","23"],["dc.bibliographiccitation.volume","106"],["dc.contributor.author","Moreira, Alvaro"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Pföhler, Claudia"],["dc.contributor.author","Kähler, Katharina C."],["dc.contributor.author","Knauss, Samuel"],["dc.contributor.author","Heppt, Markus V."],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Dimitriou, Florentia"],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Mitzel-Rink, Heidrun"],["dc.contributor.author","Schuler, Gerold"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Türk, Matthias"],["dc.contributor.author","Dummer, Reinhard"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Schröder, Rolf"],["dc.contributor.author","Heinzerling, Lucie"],["dc.date.accessioned","2020-12-10T14:23:39Z"],["dc.date.available","2020-12-10T14:23:39Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.ejca.2018.09.033"],["dc.identifier.issn","0959-8049"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72002"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1435"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","International Journal of Cancer"],["dc.bibliographiccitation.lastpage","1442"],["dc.bibliographiccitation.volume","129"],["dc.contributor.author","Kretschmer, Lutz"],["dc.contributor.author","Starz, Hans"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Satzger, Imke"],["dc.contributor.author","Voelker, Bernward"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Mitteldorf, Christina"],["dc.contributor.author","Bader, Claudia"],["dc.contributor.author","Siedlecki, Katharina"],["dc.contributor.author","Kapp, Alexander"],["dc.contributor.author","Bertsch, Hans Peter"],["dc.contributor.author","Gutzmer, Ralf"],["dc.date.accessioned","2018-11-07T08:51:44Z"],["dc.date.available","2018-11-07T08:51:44Z"],["dc.date.issued","2011"],["dc.description.abstract","In our study, we investigated the impact of the constitutional factor age on the clinical courses of melanoma patients with sentinel lymph node (SLN) biopsy. Descriptive statistics, Kaplan-Meier estimates, logistic regression analysis and the Cox proportional hazards model were used to study a population of 2,268 consecutive patients from three German melanoma centers. Younger age was significantly related to less advanced primary tumors. Nevertheless, patients younger than 40 years of age had a twofold risk of being SLN-positive (p < 0.000001). Of the young patients with primary melanomas with a thickness of 0.76 mm to 1.0 mm, 19.7% were SLN-positive. Using multivariate analysis, younger age, increasing Breslow thickness, ulceration and male sex were significantly related to a higher probability of SLN-metastasis. During follow-up, older patients displayed a significantly increased risk of in-transit recurrences (p = 0.000002) and lymph node recurrences (p = 0.0004). With respect to melanoma specific overall survival the patient's age was highly significant in the multivariate analysis. The unfavorable effect of being older was significant in the subgroups with positive and negative SLNs. Age remained also significant for the survival after the onset of distant metastases (p = 0.002). In conclusion, the patient's age is a strong and independent predictor of melanoma-specific survival in patients with localized melanomas, in patients with positive SLNs and after the onset of distant metastases. Younger patients have a better prognosis despite their higher probability of SLN metastasis. Older patients are less frequently SLN-positive but have a higher risk of loco-regional recurrence."],["dc.identifier.doi","10.1002/ijc.25747"],["dc.identifier.isi","000293245800019"],["dc.identifier.pmid","21064111"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22008"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","0020-7136"],["dc.title","Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","125"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","132"],["dc.bibliographiccitation.volume","138"],["dc.contributor.author","Salzmann, Martin"],["dc.contributor.author","Leiter, Ulrike"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Ugurel, Selma"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Enk, Alexander H."],["dc.contributor.author","Hassel, Jessica C."],["dc.date.accessioned","2021-04-14T08:23:28Z"],["dc.date.available","2021-04-14T08:23:28Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.ejca.2020.07.029"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/80932"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0959-8049"],["dc.title","Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","158"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Melanoma Research"],["dc.bibliographiccitation.lastpage","164"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Al Ghazal, Philipp"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Satzger, Imke"],["dc.contributor.author","Starz, Hans"],["dc.contributor.author","Bader, Christina"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Mitteldorf, Christina"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Kapp, Alexander"],["dc.contributor.author","Bertsch, Hans-Peter"],["dc.contributor.author","Kretschmer, Lutz"],["dc.date.accessioned","2018-11-07T09:42:15Z"],["dc.date.available","2018-11-07T09:42:15Z"],["dc.date.issued","2014"],["dc.description.abstract","Head or neck location of primary cutaneous melanomas has been described as an adverse prognostic factor, but this has to be reassessed after the introduction of sentinel lymph node (SLN) excision (SLNE). Descriptive statistics, Kaplan-Meier estimates and Cox proportional hazard models were used to study retrospectively a population of 2302 consecutive melanoma patients from three German melanoma centres undergoing SLNE. Approximately 10% of the patients (N=237) had a primary melanoma located at the head or neck (HNM). In both the SLN-positive and SLN-negative subpopulation, patients with HNM were significantly older, more frequently men and had thicker primaries compared with patients with tumours in other locations. The proportion of positive SLNs was lower in HNM compared with other locations of the primary (20 vs. 26%, P=0.048). The false-negative rate was higher in HNM (17.5 vs. 8.4%, P=0.05). In patients with HNM, the SLN status was a significant factor for recurrence-free survival but not for overall survival. SLN-negative HNM patients had a significantly worse overall survival than the SLN negatives with primaries at other sites, whereas the prognosis of the SLN-positive patients was similar in both groups. The prevalence of lymph node metastases after SLNE is lower in patients with HNM compared with other melanoma locations. As a result, the prognostic information provided by the SLN for HNM seems less important. Decision making for SLNE in HNM should be carefully balanced considering the potential morbidity of the procedure."],["dc.identifier.doi","10.1097/CMR.0000000000000042"],["dc.identifier.isi","000332601400009"],["dc.identifier.pmid","24346168"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33915"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1473-5636"],["dc.relation.issn","0960-8931"],["dc.title","Lower prevalence of lymphatic metastasis and poorer survival of the sentinel node-negative patients limit the prognostic value of sentinel node biopsy for head or neck melanomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e000333"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal for Immunotherapy of Cancer"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Amaral, Teresa"],["dc.contributor.author","Kiecker, Felix"],["dc.contributor.author","Schaefer, Sarah"],["dc.contributor.author","Stege, Henner"],["dc.contributor.author","Kaehler, Katharina"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Haferkamp, Sebastian"],["dc.contributor.author","Uttikal, Jochen"],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Rafei-Shamsabadi, David"],["dc.contributor.author","Reinhardt, Lydia"],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Karoglan, Ante"],["dc.contributor.author","Posch, Christian"],["dc.contributor.author","Gambichler, Thilo"],["dc.contributor.author","Pfoehler, Claudia"],["dc.contributor.author","Thoms, Kai"],["dc.contributor.author","Tietze, Julia"],["dc.contributor.author","Debus, Dirk"],["dc.contributor.author","Herbst, Rudolf"],["dc.contributor.author","Emmert, Steffen"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Hassel, Jessica C"],["dc.contributor.author","Meiss, Frank"],["dc.contributor.author","Tueting, Thomas"],["dc.contributor.author","Heinrich, Vanessa"],["dc.contributor.author","Eigentler, Thomas"],["dc.contributor.author","Garbe, Claus"],["dc.contributor.author","Zimmer, Lisa"],["dc.date.accessioned","2020-12-10T18:37:15Z"],["dc.date.available","2020-12-10T18:37:15Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1136/jitc-2019-000333"],["dc.identifier.eissn","2051-1426"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76892"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG study in 380 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Experimental Dermatology"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Boeckmann, L."],["dc.contributor.author","Thoms, Kai Martin"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Has, Cristina"],["dc.contributor.author","Kunz, M."],["dc.contributor.author","Kuschal, Christiane"],["dc.contributor.author","Laspe, Petra"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Struever, Diana"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T08:32:03Z"],["dc.date.available","2018-11-07T08:32:03Z"],["dc.date.issued","2009"],["dc.format.extent","311"],["dc.identifier.isi","000263520200230"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17256"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell Publishing, Inc"],["dc.publisher.place","Malden"],["dc.relation.conference","36th Annual Meeting of the Arbeitsgemeinschaft-Dermatologishche-Forschung"],["dc.relation.eventlocation","Heidelberg, GERMANY"],["dc.relation.issn","0906-6705"],["dc.title","DNA repair host factors modulate side effects of temozolomide or dacarbazinemelanoma treatment rather than treatment efficacy and are determined by promoter methylation"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","825"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Cancer Immunology, Immunotherapy"],["dc.bibliographiccitation.lastpage","834"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Kähler, Katharina C."],["dc.contributor.author","Eigentler, Thomas K."],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Heinzerling, Lucie"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Meiss, Frank"],["dc.contributor.author","Pföhler, Claudia"],["dc.contributor.author","Schlaak, Max"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Thoms, Kai M."],["dc.contributor.author","Ziemer, Mirjana"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Gutzmer, Ralf"],["dc.date.accessioned","2020-12-10T14:09:59Z"],["dc.date.available","2020-12-10T14:09:59Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s00262-018-2134-z"],["dc.identifier.eissn","1432-0851"],["dc.identifier.issn","0340-7004"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70632"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","760"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Pharmacogenetics and Genomics"],["dc.bibliographiccitation.lastpage","769"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Boeckmann, Lars"],["dc.contributor.author","Schirmer, Markus"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Struever, Diana"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Has, Cristina"],["dc.contributor.author","Kunz, Manfred"],["dc.contributor.author","Kuschal, Christiane"],["dc.contributor.author","Laspe, Petra"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T11:24:01Z"],["dc.date.available","2018-11-07T11:24:01Z"],["dc.date.issued","2009"],["dc.description.abstract","Objectives The efficacy of temozolomide (TMZ) or dacarbazine (DTIC) in melanoma treatment depends on low O-6-methylguanine-DNA-methyltransferase (MGMT) repair and on high mismatch repair. The aim of this study was to identify individual host markers for hematologic side effects and the treatment efficacy of TMZ or DTIC in melanoma treatment. Methods Fifty-one Caucasian patients with metastasized melanoma were recruited. In each patient, the mRNA expression of MGMT and two essential mismatch repair genes, MLH1 and MSH2, was measured in peripheral blood. The coding gene regions, including splice sites, were sequenced to identify genetic variants, and the promoter methylation status of the genes was determined. Results Both constitutively low and high mRNA expression of MGMT, MLH1, and MSH2 were significantly associated with reduced hematologic side effects (P=0.008-0.020), but did not correlate with treatment efficacy. We identified five variants in the MGMT gene, 13 variants in MLH1, and seven variants in MSH2, including five novel genetic variants in MLH1. Variations of the hosts' gene expression of MGMT, MLH1, and MSH2 did not result from promoter methylation. Of note, one variant in MSH2 (rs2303428) was associated with increased hematologic side effects and showed a tendency for better treatment response. Conclusion Our results indicate that either low or high host expression of MGMT, MLH1, and MSH2 may serve as a marker for reduced hematologic side effects of TMZ or DTIC, but not for treatment efficacy in melanoma. The genetic variant rs2303428 (MSH2) might serve as a predictive marker for hematologic side effects and treatment response. Pharmacogenetics and Genomics 19:760-769 (C) 2009 Wolters Kluwer Health "],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.1097/FPC.0b013e3283307cd9"],["dc.identifier.isi","000270467200004"],["dc.identifier.pmid","19741564"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56311"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1744-6872"],["dc.title","Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Oncology"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Kähler, Katharina C."],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Meier, Friedegrund"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Heppt, Markus"],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Utikal, Jochen"],["dc.contributor.author","Hassel, Jessica C."],["dc.contributor.author","Ugurel, Selma"],["dc.date.accessioned","2021-07-05T14:57:55Z"],["dc.date.available","2021-07-05T14:57:55Z"],["dc.date.issued","2021"],["dc.description.abstract","Background The combination of BRAF and MEK inhibitors has become standard of care in the treatment of metastatic BRAF V600-mutated melanoma. Clinical factors for an early prediction of tumor response are rare. The present study investigated the association between the development of an early exanthema induced by vemurafenib or vemurafenib plus cobimetinib and therapy outcome. Methods This multicenter retrospective study included patients with BRAF V600-mutated irresectable AJCC-v8 stage IIIC/D to IV metastatic melanoma who received treatment with vemurafenib (VEM) or vemurafenib plus cobimetinib (COBIVEM). The development of an early exanthema within six weeks after therapy start and its grading according to CTCAEv4.0 criteria was correlated to therapy outcome in terms of best overall response, progression-free (PFS), and overall survival (OS). Results A total of 422 patients from 16 centers were included (VEM, n=299; COBIVEM, n=123). 20.4% of VEM and 43.1% of COBIVEM patients developed an early exanthema. In the VEM cohort, objective responders (CR/PR) more frequently presented with an early exanthema than non-responders (SD/PD); 59.0% versus 38.7%; p=0.0027. However, median PFS and OS did not differ between VEM patients with or without an early exanthema (PFS, 6.9 versus 6.0 months, p=0.65; OS, 11.0 versus 12.4 months, p=0.69). In the COBIVEM cohort, 66.0% of objective responders had an early exanthema compared to 54.3% of non-responders (p=0.031). Median survival times were significantly longer for patients who developed an early exanthema compared to patients who did not (PFS, 9.7 versus 5.6 months, p=0.013; OS, not reached versus 11.6 months, p=0.0061). COBIVEM patients with a mild early exanthema (CTCAEv4.0 grade 1-2) had a superior survival outcome as compared to COBIVEM patients with a severe (CTCAEv4.0 grade 3-4) or non early exanthema, respectively (p=0.047). This might be caused by the fact that 23.6% of patients with severe exanthema underwent a dose reduction or discontinuation of COBIVEM compared to only 8.9% of patients with mild exanthema. Conclusions The development of an early exanthema within 6 weeks after treatment start indicates a favorable therapy outcome upon vemurafenib plus cobimetinib. Patients presenting with an early exanthema should therefore be treated with adequate supportive measures to provide that patients can stay on treatment."],["dc.description.abstract","Background The combination of BRAF and MEK inhibitors has become standard of care in the treatment of metastatic BRAF V600-mutated melanoma. Clinical factors for an early prediction of tumor response are rare. The present study investigated the association between the development of an early exanthema induced by vemurafenib or vemurafenib plus cobimetinib and therapy outcome. Methods This multicenter retrospective study included patients with BRAF V600-mutated irresectable AJCC-v8 stage IIIC/D to IV metastatic melanoma who received treatment with vemurafenib (VEM) or vemurafenib plus cobimetinib (COBIVEM). The development of an early exanthema within six weeks after therapy start and its grading according to CTCAEv4.0 criteria was correlated to therapy outcome in terms of best overall response, progression-free (PFS), and overall survival (OS). Results A total of 422 patients from 16 centers were included (VEM, n=299; COBIVEM, n=123). 20.4% of VEM and 43.1% of COBIVEM patients developed an early exanthema. In the VEM cohort, objective responders (CR/PR) more frequently presented with an early exanthema than non-responders (SD/PD); 59.0% versus 38.7%; p=0.0027. However, median PFS and OS did not differ between VEM patients with or without an early exanthema (PFS, 6.9 versus 6.0 months, p=0.65; OS, 11.0 versus 12.4 months, p=0.69). In the COBIVEM cohort, 66.0% of objective responders had an early exanthema compared to 54.3% of non-responders (p=0.031). Median survival times were significantly longer for patients who developed an early exanthema compared to patients who did not (PFS, 9.7 versus 5.6 months, p=0.013; OS, not reached versus 11.6 months, p=0.0061). COBIVEM patients with a mild early exanthema (CTCAEv4.0 grade 1-2) had a superior survival outcome as compared to COBIVEM patients with a severe (CTCAEv4.0 grade 3-4) or non early exanthema, respectively (p=0.047). This might be caused by the fact that 23.6% of patients with severe exanthema underwent a dose reduction or discontinuation of COBIVEM compared to only 8.9% of patients with mild exanthema. Conclusions The development of an early exanthema within 6 weeks after treatment start indicates a favorable therapy outcome upon vemurafenib plus cobimetinib. Patients presenting with an early exanthema should therefore be treated with adequate supportive measures to provide that patients can stay on treatment."],["dc.identifier.doi","10.3389/fonc.2021.672172"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87772"],["dc.notes.intern","DOI-Import GROB-441"],["dc.relation.eissn","2234-943X"],["dc.title","Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]